Secretin release after Roux-en-Y Gastric Bypass reveals a population of glucose-sensitive S-cells in distal small intestine

Ida M. Modvig1,2, Daniel B. Andersen1,2, Kaare V. Grunddal1, Rune E. Kuhre1,2, Christoffer Martinussen3, Charlotte B. Christiansen1,2, Cathrine Ørskov1, Pierre Larraufie4, Richard Kay4, Frank Reimann4, Fiona M. Gribble4, Bolette Hartmann1,2, Kirstine N. Bojsen-Møller3, Sten Madsbad3, Nicolai J. Wewer Albrechtsen1,5,6#, Jens J. Holst1,2#

1: Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

2: Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

3: Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark

4: Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, U.K.

5: Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

6: Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

#Shared co-last authors

Corresponding authors:

Professor Jens J. Holst, MD, DMSc, Department of Biomedical Sciences & Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark; Telephone: +4535327518; E-mail: jjholst@sund.ku.dk

Or Assistant Professor Nicolai J. Wewer Albrechtsen, MD, PhD, Department of Clinical Biochemistry, Rigshospitalet & Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen. Blegdamsvej 9, DK-2100 Copenhagen, Denmark; Telephone +45 29649329; E-mail: hgk795@ku.dk
Abstract

Objective: Gastrointestinal hormones contribute to the beneficial effects of Roux-en-Y gastric bypass surgery (RYGB) on glycemic control. Secretin is secreted from duodenal S-cells in response to low luminal pH, but it is unknown whether its secretion is altered after RYGB and if secretin contributes to the post-operative improvement in glycemic control. We hypothesized that secretin secretion increases after RYGB as a result of the diversion of nutrients to more distal parts of the small intestine, and thereby affects islet hormone release.

Methods: A specific secretin radioimmunoassay was developed, evaluated biochemically, and used to quantify plasma concentrations of secretin in 13 obese individuals before, 1 week after and 3 months after RYGB. Distribution of secretin and its receptor was assessed by RNA-sequencing, mass-spectrometry and in situ hybridization in human and rat tissues. Isolated, perfused rat intestine and pancreas were used to explore the molecular mechanism underlying glucose-induced secretin secretion and to study direct effects of secretin on glucagon, insulin and somatostatin secretion. Secretin was administered alone or in combination with GLP-1 to non-sedated rats to evaluate effects on glucose regulation.

Results: Plasma postprandial secretin was more than doubled in humans after RYGB (P<0.001). The distal small intestine harbored secretin expressing cells in both rats and humans. Glucose increased secretion of secretin in a sodium-glucose co-transporter dependent manner when administered to the distal part but not into the proximal part of the rat small intestine. Secretin stimulated somatostatin secretion (fold change: 1.59, P<0.05) from the perfused rat pancreas but affected neither insulin (P=0.2) nor glucagon (P=0.97) secretion. When administered to rats in vivo, insulin secretion was attenuated and
glucagon secretion increased (P=0.04), while blood glucose peak time was delayed (from 15 min to 45 min) and gastric emptying time prolonged (P=0.004).

**Conclusion:** Glucose-sensing secretin cells located in the distal part of the small intestine may contribute to increased plasma concentrations observed after RYGB. The metabolic role of the distal S-cells warrants further studies.

**Keywords:** Gastric Bypass Surgery, Glucagon-like Peptide-1, Blood glucose, Glucagon, Secretin, Secretin-receptor, Sodium Glucose Transporter

**Abbreviations:** EECs; Enteroendocrine cells, GLP-1; Glucagon-like peptide 1, RPKM; Reads Per Kilobase Million, RYGB; Roux-en-Y gastric bypass, SGLTs; sodium-glucose co-transporters, TPM; Transcripts Per Million.
1. Introduction

In the duodenum, enteroendocrine S-cells secrete secretin in response to luminal acidification and thereby regulate the intraluminal milieu by stimulating the exocrine pancreas to secrete water and bicarbonate (1). Secretin, however, also has other actions including inhibition of gastric emptying (2–4) and has been suggested to regulate secretion of the pancreatic islet hormones (5–10).

Gastrointestinal hormones, including glucagon-like peptide-1 (GLP-1), are currently used for treatment of metabolic diseases and endogenous GLP-1 contributes to the glucose lowering and weight reducing effect of Roux-en-Y gastric bypass (RYGB) (11,12). Whereas it is well established that GLP-1 secretion is increased after RYGB in humans (13), it is unknown if secretin secretion is increased.

Glucose is a powerful stimulus for GLP-1 secretion (14) and is rapidly absorbed in the upper part of the small intestine, therefore intraluminal concentrations are low in the distal part of the small intestine. We hypothesized that delivery of glucose to the distal small intestine, as seen after the diversion following RYGB, stimulates secretin secretion by luminal-sensing mechanisms. To address this, we measured plasma secretin before and after RYGB. Furthermore, we isolated and perfused the upper or lower half of the rat small intestine and studied the effect of intra-luminal glucose on secretin secretion as well as the molecular sensors involved.

To investigate potential effects of secretin on blood glucose and secretion of islet hormones, we administered secretin subcutaneously to conscious rats and perfused, in separate experiments, the rat pancreas, testing the effects of secretin on glucagon, insulin and somatostatin secretion.
2. Materials and Methods

2.1. Ethical Approvals

Human studies: Written informed consent was obtained from all study participants, and the study was approved by the Municipal Ethics Committee of Copenhagen in accordance with the Helsinki-II declaration and by the Danish Data Protection Agency, and registered at www.clinicaltrials.gov (NCT01993511).

Animal Studies: Animal studies were conducted with permission from the Danish Animal Experiments Inspectorate, Ministry of Environment and Food of Denmark, permit 2018-15-0201-01397, and in accordance with the EU Directive 2010/63/EU and guidelines of Danish legislation governing animal experimentation (1987), the National Institutes of Health (publication number 85-23), and approved by the local ethical committee (EMED, P18-336).

2.2. Peptides

GLP-1 7-36NH₂, rat and human secretin were obtained from Bachem (cat no. 4030663, cat no. 4037181 and cat no. 4031250, Bubendorf, Switzerland). Radioactive labeled rat and human secretin was obtained from Phoenix Pharmaceuticals, Inc (cat no. T-067-06 and T-067-07, CA, USA). Development and evaluation of a secretion radioimmunoassay are described in Supplementary Materials 1.
2.3. Mixed meal tests before and after Roux-en-Y Gastric Bypass surgery in obese subjects

Plasma obtained during a standardized liquid mixed-meal test (MMT) before, one week and three months after RYGB from 13 obese subjects (type 2 diabetes; n=4, impaired glucose tolerance; n=3, normal glucose tolerance; n=6) was analyzed. Glucose tolerance was determined by standard OGTT preoperatively. All samples were from a study by Martinussen et al as previously described (15).

2.4. Distribution of secretin and GLP-1 along the gastrointestinal tract in humans and rats

Mass-spectrometry based detection was used to assess distribution of secretin and GLP-1 (for comparison) in human intestinal tissue as described previously (16). The secretin and GLP-1 profiles are presented as peak area divided by tissue weight.

Whole wall tissue biopsies (~1 cm) of esophagus, ventricle, duodenum, proximal jejunum, distal ileum and colon were collected from non-fasted rats (anatomical definitions are listed in Supplementary Table 1). Peptides in tissue biopsies were extracted using trifluoroacetic acid (Supplementary Materials 2), and immunohistochemical staining of secretin-positive cells was performed on paraffin embedded tissue samples using anti-secretin (5585-3), a generous gift from Professor Jan Fahrenkrug (Supplementary Materials 3).

2.5. Animal experiments

Male Wistar rats (200-250 g) were obtained from Janvier (Le Genest-Saint-Isle, France) and housed two to four rats per cage. Rats were allowed one week of acclimatization and kept on a 12 h light/dark cycle with ad libitum access to water and standard chow.
2.5.1 Isolated perfused rat small intestine and pancreas

Perfusion was performed using a single pass perfusion system (UP100, Hugo Sachs Harvard Apparatus, Germany). The rat small intestine and pancreas were surgically isolated (as described in Supplementary Materials 4). Each protocol started with a baseline period followed by addition of various test substances. Test stimulants used in the perfused intestine included 0.1 M HCl, 0.1 M NaHCO₃, 0.05 M KCl (Sigma-Aldrich, Brøndby, Denmark), 20% (w/v) D-glucose (cat no. G8270, Sigma-Aldrich, Denmark) and 10 mmol/L Phloridzin (cat no. P3449, Sigma-Aldrich, Denmark). Test stimulants used in the perfused pancreas were 1 nmol/L GLP-1 7-36NH₂ and both 20 pmol/L and 2 nmol/L secretin.

2.5.2 In vivo experiments in rats

Experiments were carried out on 2 occasions on fasted rats (300±13 g) just before their nocturnal feeding period (5:00 PM). Rats were divided into weight-matched groups (n=8/group). At -10 minutes, 200 μL tail blood was collected into pre-chilled EDTA-coated capillary tubes (catalog no. 200 K3E, Microvette; Sarstedt, Nümbrecht, Germany) and instantly transferred onto ice. At -5 minutes, 300 uL test solution was injected subcutaneously. Test solutions were isotonic saline, (negative control) or peptides prepared in isotonic saline: secretin (30 nmol/kg), GLP-1 (30 nmol/kg) or secretin+GLP-1 (both 30 nmol/kg). At 0 minutes, a bolus of D-glucose (2 g/kg) and acetaminophen (100 mg/kg), prepared in isotonic saline, was given orally. Rats from the same cage received different treatments. Blood was collected at times -10, -5, 5, 15, 30, 45, 60 and 90 min. Glucose was measured immediately after blood collection, while the remainder of the samples were instantly transferred onto ice and centrifuged (1,650 g, 4°C, 10 min) within half an hour to obtain plasma. Plasma was transferred to Eppendorf tubes, immediately frozen on dry ice and stored at −20°C until analysis.
2.5.3 *Biochemical measurements of perfusion effluents, rat blood and rat plasma*

Perfusion effluents: Insulin was measured with antiserum (code no. 2006-3) which cross-reacts with rodent insulin I and II (17). Glucagon was measured with an antibody directed against the C-terminus (code no. 4305) as previously described (18). Total GLP-1 (the sum of 7-36NH₂, 9-36NH₂ and potential mid-terminal cleaved fragments) was measured using a C-terminal specific radioimmunoassay targeting amidated forms (code no. 89390) (19). Somatostatin was measured using a side-viewing antibody (code no. 1758-5), detecting all bioactive forms of somatostatin (20,21).

Blood glucose was measured using a glucometer (Accu-Chek Mobile, catalog no. 05874149001; Roche Diagnostics, Mannheim, Germany). Plasma concentrations of glucagon were measured by sandwich ELISA (catalog no. 10-1281-01; Mercodia AB, Uppsala, Sweden) (22). Plasma concentrations of insulin and C-peptide were measured using ELISAs (catalog no. 10-1250-01 and 10-1172-01; Mercodia AB, Uppsala, Sweden).

2.6. *RNA sequencing of human islets*

Publicly available RNaseq dataset (from GSE85241, GSE81608 and E-MTAB-5061 (23–25)) were obtained. Average Reads Per Kilobase Million (RPKM) values for secretin receptor (SCTR) and GLP-1 receptor (GLP-1R) were uploaded to the Jupyter Notebook (http://jupyter.org/). Data were then log2 transformed and mean expression levels were calculated in alpha, beta and delta cells, respectively. We excluded individuals with diabetes from these analyses. For further details about the donors, isolation of cells and RNA-sequencing methods please see the original studies (23–25).

*In situ* hybridization on rat pancreases is described in Supplementary Materials 5.
2.7. Statistical analysis

Clinical samples and in vivo data: Plasma concentrations of hormones were evaluated using area under the curve analysis and statistical testing by one-way ANOVA followed by Holm-Sidak multiple comparisons test. A mixed-effect model was applied in order to test the effect of treatment and time on the variables.

Perfusion experiments: Data are expressed as mean±SEM concentrations in venous effluents (pmol/L). Since the perfusion flow was kept constant through the experiments, this mirrors the actual secretion output (which can be calculated by multiplying with the flow rate). To test for statistical significance, mean values within the test period (based on 10 subsequent minutes) were compared with mean values in the baseline period (10 subsequent minutes prior to test stimulant administration) using statistical testing as described above.

Calculations were made using STAT14 (SE), College Station, Texas, USA. For illustrations, GraphPad Prism version 8.0 (GraphPad Software, La Jolla California USA) and Adobe CC software suite were used (San Francisco, CA, USA). P-values < 0.05 were considered statistically significant. Data are shown as means±SEM.
3. Results

3.1. Development of a sensitive secretin assay

We generated titer curves for three different antibodies against human secretin (structure in Figure 1A) using two radioactive iodine-labeled secretin peptides (termed tracer). Based on binding characteristics, the antibody named 5595-3 was selected for further testing and for preparation of calibrator curves (Supplementary Figure 1). By sequencing alignment, we found that human and rat secretin differ at position 14-16 (human: REG vs. rat: QDS) (Figure 1A) but no species variation was found within the antibody’s epitope (position 18-27) (Figure 1A). For rat samples, we therefore used the same antibody and tracer. For calibrating purposes, we included the rat isoform of secretin as calibrator control. Recovery of human secretin added to human pooled plasma was calculated to 71±11% (mean±SD) with a lower limit of detection of 1 pmol/L and a dynamic range from 2.5 pmol/L to 80 pmol/L (Supplementary Figure 1) using solvent phase-extraction (70% ethanol). We did not observe cross-reactivity (not significantly different compared to background) towards CCK, glucagon, glicentin, GLP-1, human insulin, oxyntomodulin, neurotensin and PYY at concentrations up to 300 pmol/L.

3.1.1. Comparison of Commercial ELISAs

The two commercially available ELISAs had low recoveries of human secretin of 15%±8% (mean±SD) in assay buffer. A Bland-Altman analysis (comparing the concentrations measured using the two ELISAs to the in-house developed RIA) showed acceptable (less than 2SD) degree of variation for concentrations above 20 pmol/L, however, for physiological plasma concentrations of secretin (<20pmol/L) the two commercial ELISAs were inadequate (Supplementary Figure 2).
Having developed a specific and sensitive secretin radioimmunoassay, we next investigated whether postprandial plasma secretin concentrations are elevated after RYGB surgery.

**3.2. Roux-en-Y Gastric Bypass surgery increases meal-induced secretin release in obese individuals**

Fasting plasma concentrations of secretin were not significantly different after comparison with before RYGB (Figure 1B, P>0.45), whereas postprandial plasma secretin concentrations in response to a liquid meal test were significantly increased three months after compared with before RYGB (P<0.05), reaching a 2-3 fold higher peak value, and total AUCs were approximately doubled (tAUC0-180min: 569±475 vs. 956±360 pmol/L x min) (Figure 1C). Concentrations were also increased one week after RYGB but to a more modest degree and total AUCs did not differ from pre-operative AUCs (P=0.67).

**3.3. Distribution of secretin in humans and rats**

Using publicly available RNA-seq data from 37 different human tissues (26) expression profiles of secretin showed a maximum in the duodenum, as expected. However, high levels were also found in the more distal parts of the small intestine (Figure 1D), consistent with previous reports on secretin distribution in other species (27,28). Mass-spectrometry analysis on human gastrointestinal tissue revealed that secretin concentrations were highest in the duodenum as well as in jejunal biopsies (Figure 1E). Concentrations of GLP-1 7-36NH₂ were included as positive controls. GLP-1 concentration was highest in the distal part of the gastrointestinal tract (ileum, colon and rectum) (Figure 1E) in line with previous reports (29).

To examine if the distribution of secretin in rats was similar to humans, we measured the concentration of extractable secretin from esophagus to colon in rats (Supplementary Table 1). Secretin was not
detectable in esophagus and the ventricle (Figure 1F, n=7) but in the duodenum and in the distal ileum, secretin was found at comparable concentrations ~20-30 pmol/g tissue (Figure 1F, n=7). Concentrations of GLP-1 increased from duodenum to colon with the highest concentration in the distal ileum (~60 pmol/g tissue) (Figure 1F, n= 7) in line with a previous report (30). Immunohistochemical stainings of secretin (Figure 1G+H) showed no staining in esophagus, ventricle and colon and high intensity in proximal jejunum and distal ileum, consistent with the measured extractable concentrations.

3.4. Secretin responses from the proximal and distal small intestine using the isolated perfused rat intestine model

Luminal infusion of HCl increased secretin secretion 4-fold (Baseline: 3.7±0.9 vs HCl: 15.6±2.3 pmol/L, P<0.05, n=6) (Figure 2A+B). Following HCl infusion, the intestine was flushed with sodium bicarbonate (0.1 M) to neutralize luminal pH (Figure 2A). This returned secretin secretion to pre-HCl-stimulatory levels. KCl (0.05 M) was infused intra-vascularly at the end of the experiment (Figure 2A). Secretion of secretin increased significantly compared to preceding baseline secretion (Baseline: 5.2±0.8 vs. KCl: 9.1±0.9 pmol/L, P<0.05, n=6) (Figure 2B). Our data therefore suggests that cell depolarization is involved in secretin release from the perfused rat small intestine and furthermore that our perfusion model reflects the physiology of secretin secretion. We therefore decided to evaluate potential differences in HCl and glucose-induced secretin secretion in the proximal and distal small intestine using this model.
3.4.1. Differential sensing of glucose by secretin producing cells in the proximal and distal small intestine

Luminal HCl infusion increased secretin secretion (P<0.05) from both the proximal and distal half of the small intestine, but to the greatest extent in the distal half (baseline-subtracted values; Proximal. HCl: 7.6±1.5 vs. Distal. HCl: 16.3±2.6 pmol/L, P<0.05, n=6) (Figure 2C+D). Of particular notice, distal, but not proximal, infusion of glucose resulted in a significant (P<0.05) secretin response (baseline-subtracted values; Proximal. Glucose: 0.48±0.3 vs Distal. Glucose: 4.3±1 pmol/L, n=6) (Figure 2C+D) suggesting that distally located secretin cells are capable of sensing glucose.

GLP-1 secretion was measured as this is a well validated control in this experimental setup (31,32). Secretion of GLP-1 in response to both glucose and HCl infusion was likewise significantly higher from the distal small intestine compared to the proximal small intestine (Figure 2E+F), which is consistent with high extractable concentrations of GLP-1 in the distal small intestine (Figure 1F).

3.4.2. Glucose induced secretin secretion from the distal small intestine is mediated by sodium-glucose co-transporter

Inhibition of SGLT with the competitive SGLT1/2 inhibitor, phlorizdin, eliminated glucose-stimulated secretin response from the distal rat small intestine (baseline-subtracted values; Glucose: 1.9±0.7 vs. Glucose + Phloridzin: 0±0.2 pmol/L, P<0.05, n=6) (Figure 2G+H), indicating that sodium-coupled glucose absorption is involved in the mechanism of glucose stimulated secretin secretion from the distal rat small intestine.

Consistent with previous reports (33,34), phloridzin eliminated glucose-stimulated GLP-1 secretion from the distal rat small intestine (baseline-subtracted values; Glucose: 38.5±10.4 vs. Glucose+Phloridzin: 2.6±1.2 pmol/L, P<0.05, n=6) (Figure 2I+J). HCl was included as a positive control for secretin secretion in the end of each experiment.
3.5. Secretin delays blood glucose peak time and increases plasma glucagon in non-sedated rats

Blood glucose concentrations were similar across groups at baseline (P>0.71). Peak times for blood glucose were prolonged from 15 min (saline group) to 30 min (GLP-1), 45 min (secretin), and 60 min (secretin+GLP-1) (Figure 3A) but the incremental area under the curve (iAUC$_{0-90\text{min}}$) was not significantly different between groups (P>0.77, Figure 3B). Gastric emptying, reflected by changes in plasma acetaminophen concentrations, was markedly prolonged in secretin treated rats compared to saline and GLP-1 treated groups (P<0.05, Figure 3C+D). GLP-1 had significant effect on plasma acetaminophen at the initial time points compared to saline (P<0.05).

Plasma concentrations of insulin and C-peptide mirrored blood glucose levels (Figure 3E+G). However, in rats receiving both secretin and GLP-1, insulin and C-peptide peaked 5 minutes after the oral glucose gavage at which time point no change in blood glucose levels were observed (Figure 3A). When comparing iAUC$_{0-90\text{min}}$ of insulin and C-peptide, there was a tendency towards a lowering effect of secretin and GLP-1, but neither reached statistical significance (Secretin vs. Saline; P$_{\text{insulin}}$=0.07 and P$_{\text{C-peptide}}$=0.09, GLP-1 vs. Saline; P$_{\text{insulin}}$=0.09 and P$_{\text{C-peptide}}$=0.55 and Secretin+GLP-1 vs Saline; P$_{\text{insulin}}$=0.69 and P$_{\text{C-peptide}}$=0.44) (Figure 3F+H).

Glucose administration lowered plasma glucagon concentrations in all groups (Figure 3I). However, secretin (either alone or in combination with GLP-1) treated rats had a significantly increased plasma concentration of glucagon during the first five minutes after administration (Secretin: 9.7±1.1 vs. Saline: 6.5±1.4 pmol/L, P=0.04 and Secretin+GLP-1: 9.8±0.7 vs. Saline: 6.5±1.4 pmol/L, P=0.03) but after 30 minutes, levels were similar to those in the control group. Glucagon n-AUCs were lower in the group receiving GLP-1 compared to saline group (P=0.08) and to the secretin-treated group (P<0.05) (Figure 3J).
3.6. Pancreatic delta cells express the secretin receptor (Sctr) and exogenous secretin increases somatostatin secretion from the perfused rat pancreas

To evaluate the potential metabolic effects of increased secretin release, we initially assessed tissue specific enrichment of the Sctr. We found that aside from the known expression of secretin receptors in the duodenum, pancreatic tissue contained the secretin receptor transcript (Figure 4A). However, since these values represent both expression in exocrine acinar/ductular tissue and islets, we next investigated if Sctr was present in human islets. Sctr was expressed in delta-cells and detectable at lower levels in alpha and beta-cells (Figure 4B). Sctr expression were compared to Glp-1r profiles, which, expectedly, showed high expression in the beta cells and, to a lesser extent, in the delta cells (Figure 4B). To investigate the translational relevance of rat islets to humans in regard to Sctr expression, we used an in situ hybridization approach. The Sctr was primarily found to be expressed in pancreatic delta-cells and to a lesser extent in the alpha and beta-cells of the rat (Figure 4C).

To examine whether secretin has an insulinotropic effect on the rat pancreas, we perfused the rat pancreas with 10 mmol/L glucose and administered secretin at a concentration matching post-RYGB concentrations as well as a supra-physiological concentration (20 pmol/L and 2 nmol/L respectively) (Figure 4D+E). GLP-1 was infused at the end of the experiment (1 nmol/L) as a positive control for insulin and somatostatin release (35–37). Secretion of insulin continuously increased throughout the experiment independent of secretin infusion (because of the elevated glucose concentration), and the baseline secretion of insulin was therefore calculated as the average secretion before and after secretin stimulation. Insulin did not increase in response to both of the applied concentrations of secretin (Baseline: 325±34 vs. Secretin (20 pmol/L): 365.9±35.2 pmol/L, P=0.13 and Baseline: 426.8±41.7 vs. Secretin (2 nmol/L): 454 ±36.8 pmol/L, P=0.56, n=6) (Figure 4E).
Consistent with the expression of the Sctr in rat and human delta-cells, secretin infusion significantly increased secretion of somatostatin (Baseline: 8.3±1.1 vs. Secretin (20 pmol/L): 13.3±1.9 pmol/L, P<0.05 and Baseline: 9.8±1.6 vs. Secretin (2 nmol/L): 14.9±2.6 pmol/L, P<0.05, n=6) (Figure 4F+G).

Glucagon secretion was low, due to the high glucose concentration in the perfusion buffer, and neither secretin nor GLP-1 infusions led to significant changes in its secretion (P>0.18, n=6) (Figure 4H+I).
4. Discussion

Here, we demonstrate that postprandial plasma concentrations of secretin are increased after RYGB surgery in obese individuals. This may result from the anatomical rearrangement of the small intestine which diverts luminal nutrients, like glucose, to more distal sites of the small intestine. Increased villus length after RYGB may also contribute the observed changes in plasma secretin concentrations (38). Tissue levels of secretin have been reported to be up-regulated in a rodent model of RYGB (39) but post-operative plasma concentrations of secretin have to our knowledge not been reported previously.

Furthermore, we show that secretin, besides in the duodenum, is expressed in the distal small intestine in humans and rats, and using a physiologically relevant model: the perfused rat intestine (31), we demonstrate that glucose is a strong stimulus for secretin release from the distal but not from the proximal rat small intestine. Using an inhibitor of SGLT1/2 activity (phloridzin) (34) we found that the molecular mechanism responsible for glucose-induced secretin secretion involves glucose absorption through the SGLT. SGLT-2 inhibition has gained major clinical interest due to its glucose lowering effect and reduced risk of cardiovascular disease (40). One may therefore speculate that patients treated with non-selective SGLT inhibitors would have an altered secretin secretion profile, similar to what has been reported for GLP-1 (41) but this remains to be explored. Previous attempts to show glucose-induced secretin secretion have been negative (7,42–44), probably because in these studies glucose was administered to the proximal rather than the distal part of the small intestine.

Glucose-stimulated secretin release from the distal small intestine is probably not of major physiological importance in un-operated humans since glucose mainly is absorbed in the proximal part of the small intestine. However, after intake of large carbohydrate rich meals, some intraluminal glucose may reach more distal parts of the small intestine (45), and secretion may under these circumstances play a role
together with GLP-1 in improving glycemic control by inhibition of gastric emptying. This putative effect is supported by our in vivo data and consistent with previous findings (2–4).

Intraluminal acidification in the distal small intestine resulted in a larger secretory secretin response compared to the proximal intestine. The physiological relevance of this finding is not clear. The acidity of the gastric chyme entering the upper part of the small intestine is rapidly neutralized by a mixture of bile, mucosal - and pancreatic bicarbonate secretion, but the stimulatory effect of low pH in the distal small intestine on secretin-secreting cells may reflect a safety mechanism to reduce gastric emptying. The fact that also GLP-1 secretion was increased, may point to a more general effect, however, where hydrogen ions formed during digestion and perhaps fermentation in the mucosa micromilieu, stimulate ileal endocrine cells to activate the ileal brake. Further studies are required to investigate this new unexpected observation.

The observations regarding the effects of secretin on pancreatic islets are conflicting (6,7,46–50). Our data support that physiological levels of secretin regulate pancreatic secretion of somatostatin which is consistent with Sctr expression in rat and human delta-cells. Although Sctr was also expressed by beta-cells, secretin did not affect insulin secretion in the perfused rat pancreas whereas in vivo secretin actually led to lowering of plasma insulin levels early after an OGTT. The underlying reason for this awaits further investigation but this may be related to prolonged gastric emptying time and to an increased secretion of somatostatin which through paracrine effects may have overruled potential direct stimulatory effects of secretin on insulin secretion. Glucagon secretion was also not affected but this may be due to the already low levels when the pancreas was perfused in hyperglycemic conditions, thereby restricting the capability to detect further inhibition of alpha cells. However, to our surprise, there was a short-lasting increase in glucagon secretion after secretin injection in vivo, which was uninfluenced by the
glucagonostatic effect of GLP-1 (51) and sympathetic stress (as this was not observed in the control group), as observed when similar doses of both peptides were injected. The underlying reason(s) is not clear.

5. Conclusion
Our study expands the current knowledge regarding secretin physiology and suggest that the RYGB-related increase in plasma secretin concentrations is mediated by nutrients reaching S-cells located in the distal small intestine. The physiological role of glucose-sensing S-cells warrant further studies but given secretin’s potential effects on islet secretion and whole-body metabolism (52) it may be speculated that secretin contribute to the metabolic effects of RYGB.

6. Author contribution
Conceived and designed research: IMM, NJWA, and JJH. Performed experiments: DBA, KVG, REK, CBC, CØ, BH, and IMM. Provided clinical samples: CM, KNBM and SM. Provided Mass-spectrometry data: PL, RK, FR, and FG. Analyzed data: IMM and NJWA. Interpreted results of experiments: IMM and NJWA. Prepared figures: IMM and NJWA. Drafted manuscript: IMM, and NJWA. All authors edited and revised the manuscript and approved the final version.

7. Conflicts of interest
No conflicts of interest, financial or otherwise, are declared by the authors.
8. Acknowledgement

The study was supported by a grant from the European Research Council (grant no. 695069) to JJH and by an Excellence Emerging Investigator Grant—Endocrinology and Metabolism (NNF19OC0055001) to NJWA.
**Figure 1: Secretion of secretin after Roux-en Y Gastric Bypass surgery and distribution of secretin in rats and in humans.** A: Structure of human and rat secretin and antibody binding in the secretin assay. SP: signal peptide. Red capitals: differences between rat and human peptide sequences. Highlighted capitals: Ab epitope. B: Postprandial plasma concentrations of secretin before (pre), one week (1 week) and three months (3 month) after RYGB surgery in obese individuals, n=13. C: Calculated total area under the curve (tAUC0-180) is shown for panel B. D: Expression profiles of secretin in human tissues. RNA-seq data from human tissues presented as Transcripts Per Million (TPM) (26). E: Distribution of secretin and GLP-1 in human intestinal tissue. Mass-spectrometry profiling of secretin and GLP-1 in the human gastrointestinal tract. Levels of secretin and GLP-1 are presented as peak area divided by tissue weight, n=2-9 (16). F: Extractable secretin and GLP-1 concentrations in whole-wall biopsies along the rat gastrointestinal tract (pmol/g tissue), n=7 male Wistar rats. G: Immunohistochemical staining of secretin in the rat gastrointestinal tract (Ab:5585-21 in human tissues presented as Transcripts Per Million (TPM) (26)). Highlighted capitals: Ab epitope. J.: Sodium-coupled glucose transporters (SGLT) are involved in distal glucose sensing. Glucose (20% w/v) was infused intra-luminally between minute 26-55 as a positive control for secretin release. C: Secretin concentrations (pmol/L). D: Mean baseline-subtracted secretin concentrations in response to glucose and HCl stimulation. E: GLP-1 concentrations (pmol/L). F: Mean baseline-subtracted GLP-1 concentrations in response to glucose and HCl stimulation. C-J.: Sodium-coupled glucose transporters (SGLT) are involved in distal glucose sensing. Glucose (20% w/v) was infused intra-luminally between minute 26-55 as a positive control for secretin release. C: Secretin concentrations (pmol/L). D: Mean baseline-subtracted secretin concentrations in response to glucose and HCl stimulation with and without phloridzin. I: GLP-1 concentrations (pmol/L). J: Mean baseline-subtracted GLP-1 concentrations in response to HCl stimulation and glucose stimulation with and without phloridzin.

Data are shown as means ± SEM. P>0.05. *P<0.05, **P<0.01, ****P<0.0001 by a One-way ANOVA with correction for multiple testing (Holm-Sidak).
Figure 3. Effects of secretin and GLP-1 on glucose metabolism in non-sedated rats. Secretin (30 nmol/kg), GLP-1 (30 nmol/kg) or Secretin + GLP-1 (both 30 nmol/kg) were subcutaneously injected at timepoint -5 min. At timepoint 0, a mixture of oral glucose (2g/kg) and acetaminophen (25 mg/mL) was given. **A**: Blood glucose concentrations (mmol/L). **B**: Incremental area under the curve (iAUC<sub>0.90</sub>) of blood glucose concentrations shown in panel A. There were no significant differences in iAUC<sub>0.90</sub> between the groups (P>0.77). **C**: Plasma acetaminophen concentrations (μg/mL). **D**: iAUC<sub>0.90</sub> of acetaminophen concentrations. Acetaminophen concentrations in the group receiving secretin were significantly decreased compared to the control group (P<0.05) and to the group receiving GLP-1 (P<0.05). **E**: Plasma concentrations of insulin (pmol/L) **F**: iAUC<sub>0.90</sub> of insulin concentrations. There were no significant differences in iAUC between the four groups (P>0.08). **G**: Plasma concentrations of C-peptide (pmol/L) **H**: iAUC<sub>0.90</sub> of C-peptide concentrations. There were no significant differences between the groups (P>0.09). **I**: Plasma glucagon concentrations (pmol/L) **J**: iAUC<sub>0.90</sub> of glucagon concentrations. Secretion of glucagon was significantly decreased in the group receiving GLP-1 compared to the group receiving secretin (P<0.05). There were no significant differences between all other groups (P>0.32).

Data are shown as means ± SEM. P>0.05. **P<0.05, ***P<0.01, ****P<0.001, by a One-way ANOVA with correction for multiple testing (Holm-Sidak), n=31 male Wistar rats (7-8 per group).

Figure 4. Expression of the secretin receptor (Sctr) and the effects of exogenous secretin on the perfused rat pancreas. **A**: Expression profiles of Sctr in human tissues. RNA-seq data from human tissues presented as Transcripts Per Million (TPM) (26). **B**: Expression of Sctr and Glp-1r in human non-diabetic islets. RNA-seq data from human alpha, beta and delta cells presented as Reads Per Kilobase Million (RPKM) (23–25). **C**: Dual in situ hybridization and immunohistochemical staining of Sctr mRNA transcripts in rat pancreatic islets. Representative images of pancreatic islets containing in situ hybridization stained Sctr mRNA transcripts (red) and immunohistochemically stained insulin (1), glucagon (2) and somatostatin (3) (green) cells with blow-up areas. Each red dot represents a single stained mRNA transcript. Arrows indicate overlap between Sctr mRNA staining and peptide hormone staining. Dashed line outline border between pancreatic islets and exocrine pancreas. Nuclei was visualized with DAPI counterstaining (blue). Arrows indicate staining overlap. Overview scale bar, 50 μm. Blow-up scale bar, 5 μm, n=4 male Wistar rats. **D-I**: Effects of exogenous secretin on the perfused rat pancreas. Secretin (20 pmol/L) was infused between minute 16-30 and Secretin (2 nmol/L) was infused between minute 51-65. GLP-1 (1 nmol/L) was infused between minute 86-95 as a positive control for insulin secretion **D**: Insulin concentrations (pmol/L). **E**: Mean concentrations of insulin at baseline (Baseline 1, 2 and 3) and following stimulation with either 20 pmol/L secretin, 2 nmol/L secretin or 1 nmol/L GLP-1. **F**: Somatostatin concentrations (pmol/L). **G**: Mean concentrations of somatostatin at baseline (Baseline 1, 2 and 3) and following stimulation with either 20 pmol/L secretin, 2 nmol/L secretin or 1 nmol/L GLP-1. **H**: Glucagon concentrations (pmol/L). **I**: Mean concentrations of glucagon at baseline (Baseline 1, 2 and 3) and following stimulation with either 20 pmol/L secretin, 2 nmol/L secretin or 1 nmol/L GLP-1.
Data are shown as means ± SEM. P>0.05. *P<0.05, **P<0.01 by a One-way ANOVA with correction for multiple testing (Holm-Sidak), n=6 male Wistar rats for all groups.
References

1. Bayliss WM, Starling EH. The mechanism of pancreatic secretion. The Journal of physiology [Internet]. 1902 Sep 12 [cited 2019 Jun 13];28(5):325–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16992627

2. Raybould HE, Holzer H. Secretin inhibits gastric emptying in rats via a capsaicin-sensitive vagal afferent pathway. European journal of pharmacology [Internet]. 1993 Nov 30 [cited 2019 Aug 13];250(1):165–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8119315

3. Valenzuela JE, Defilippi C. Inhibition of Gastric Emptying in Humans by Secretin, the Octapeptide of Cholecystokinin, and Intraduodenal Fat. Gastroenterology [Internet]. 1981 Nov 1 [cited 2019 Aug 13];81(5):898–902. Available from: https://www.gastrojournal.org/article/S0016-5085(81)80115-1/abstract

4. Vagne M, Andre C. The Effect of Secretin on Gastric Emptying in Man. Gastroenterology [Internet]. 1971 Mar 1 [cited 2019 Aug 14];60(3):421–4. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0016508571801221

5. Glaser B, Shapiro B, Glowniak J, Fajans SS, Vinik AI. Effects of Secretin on the Normal and Pathological β-Cell. The Journal of Clinical Endocrinology & Metabolism [Internet]. 1988 Jun 1 [cited 2019 Aug 13];66(6):1138–43. Available from: https://academic.oup.com/jcem/article-lookup/doi/10.1210/jcem-66-6-1138

6. Hisatomi A, Unger RH. Secretin Inhibits Glucagon in the Isolated Perfused Dog Pancreas. Diabetes [Internet]. 1983 Oct 1 [cited 2019 Aug 15];32(10):970–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6137431

7. Fahrenkrug J, Schaffalitzky de Muckadell OB, Kühl C. Effect of secretin on basal- and glucose-stimulated insulin secretion in man. Diabetologia [Internet]. 1978 Apr [cited 2019 Aug 15];14(4):229–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/565310

8. Dupré J, Chisholm DJ, McDonald TJ, Rabinovitch A. Effects of Secretin on Insulin Secretion and Glucose Tolerance. Canadian Journal of Physiology and Pharmacology [Internet]. 1975 Dec [cited 2019 Aug 15];53(6):1115–21. Available from: http://www.nrcresearchpress.com/doi/10.1139/y75-155

9. Unger RH, Ketterer H, Dupré J, Eisentraut AM. The effects of secretin, pancreozymin, and gastrin on insulin and glucagon secretion in anesthetized dogs. The Journal of clinical investigation [Internet]. 1967 Apr [cited 2019 Aug 15];46(4):630–45. Available from: http://www.ncbi.nlm.nih.gov/pubmed/4290022

10. Unger RH, Ketterer H, Eisentraut A, Dupré J. Effect of secretin on insulin secretion. The Lancet [Internet]. 1966 Jul 2 [cited 2019 Aug 15];288(7453):24–6. Available from: https://www.sciencedirect.com/science/article/pii/S0140673666917491?via%3Dihub

11. Adams TD, Davidson LE, Litwin SE, Kim J, Kolotkin RL, Nanjee MN, et al. Weight and Metabolic Outcomes 12 Years after Gastric Bypass. New England Journal of Medicine [Internet]. 2017 Sep 21 [cited 2019 Aug 15];377(12):1143–55. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1700459

12. Larraufie P, Roberts GP, McGavigan AK, Kay RG, Li J, Leiter A, et al. Important Role of the GLP-1 Axis for Glucose Homeostasis after Bariatric Surgery. Cell Reports [Internet]. 2019 Feb 5 [cited 2019
13. Holst JJ, Madsbad S. Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor. Surgery for Obesity and Related Diseases [Internet]. 2016 Jul [cited 2019 Aug 16];12(6):1236–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27313194

14. Adriaenssens AE, Reimann F, Gribble FM. Distribution and Stimulus Secretion Coupling of Enteroendocrine Cells along the Intestinal Tract. In: Comprehensive Physiology [Internet]. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2018 [cited 2019 Sep 17]. p. 1603–38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30215862

15. Martinussen C, Bojsen-Møller KN, Dirksen C, Jacobsen SH, Jørgensen NB, Kristiansen VB, et al. Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass. American journal of physiology Endocrinology and metabolism [Internet]. 2015 Mar 15 [cited 2019 Jun 17];308(6):E535-44. Available from: http://www.physiology.org/doi/10.1152/ajpendo.00506.2014

16. Roberts GP, Larraufie P, Richards P, Kay RG, Galvin SG, Miedzybrodzka EL, et al. Comparison of Human and Murine Enteroendocrine Cells by Transcriptomic and Peptidomic Profiling. Diabetes [Internet]. 2019 May [cited 2019 Jun 20];68(5):1062–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30733330

17. Brand CL, Jorgensen PN, Knigge U, Warberg J, Svendsen I, Kristensen JS, et al. Role of glucagon in maintenance of euglycemia in fed and fasted rats. The American journal of physiology. 1995 Sep;269(3 Pt 1):E469-77.

18. Orskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. The Journal of Clinical Investigation [Internet]. 1991 Feb 1;87(2):415–23. Available from: https://doi.org/10.1172/JCI115012

19. Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes [Internet]. 1994 Apr 1 [cited 2019 Jun 17];43(4):535–9. Available from: http://diabetes.diabetesjournals.org/cgi/doi/10.2337/diab.43.4.535

20. Baldissera FGA, Nielsen O V., Holst JJ. The intestinal mucosa preferentially releases somatostatin-28 in pigs. Regulatory Peptides [Internet]. 1985 Jul [cited 2019 Jun 12];11(3):251–62. Available from: https://linkinghub.elsevier.com/retrieve/pii/01670115858900576

21. Hilsted L, Holst JJ. On the accuracy of radioimmunological determination of somatostatin in plasma. Regulatory Peptides [Internet]. 1982 Jun [cited 2019 Jun 12];2(1):13–31. Available from: https://linkinghub.elsevier.com/retrieve/pii/0167011582901057

22. Wewer Albrechtsen NJ, Kuhre RE, Windeløv JA, Ørgaard A, Deacon CF, Kissow H, et al. Dynamics of glucagon secretion in mice and rats revealed using a validated sandwich ELISA for small sample volumes. American Journal of Physiology-Endocrinology and Metabolism [Internet]. 2016 Aug 1 [cited 2019 Aug 19];311(2):E302–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27245336

23. Xin Y, Kim J, Okamoto H, Ni M, Wei Y, Adler C, et al. RNA Sequencing of Single Human Islet Cells Reveals Type 2 Diabetes Genes. Cell Metabolism [Internet]. 2016 Oct 11 [cited 2019 Jun 14];24(4):608–15. Available from: https://www.sciencedirect.com/science/article/pii/S155041311630434X
24. Muraro MJ, Dharmadhikari G, Grün D, Groen N, Dielen T, Jansen E, et al. A Single-Cell Transcriptome Atlas of the Human Pancreas. Cell systems [Internet]. 2016 [cited 2019 Jun 14];3(4):385-394.e3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27693023

25. Segerstolpe Å, Palasantza A, Eliasson P, Andersson E-M, Andréasson A-C, Sun X, et al. Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes. Cell Metabolism [Internet]. 2016 Oct 11 [cited 2019 Jun 14];24(4):593–607. Available from: https://www.sciencedirect.com/science/article/pii/S1550413116304363

26. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue-based map of the human proteome. Science [Internet]. 2015 Jan 23 [cited 2019 Jun 19];347(6220):1260419. Available from: https://science.sciencemag.org/content/347/6220/1260419

27. Polak JM, Coulling I, Bloom S, Pearse AG. Immunofluorescent localization of secretin and enteroglucagon in human intestinal mucosa. Scandinavian journal of gastroenterology [Internet]. 1971 [cited 2019 Aug 2];6(8):739–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/4945081

28. Van Ginneken C, Weyns A. A stereological evaluation of secretin and gastric inhibitory peptide-containing mucosal cells of the perinatal small intestine of the pig. Journal of anatomy [Internet]. 2004 Oct [cited 2019 Aug 2];205(4):267–75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15447686

29. Eissele R, Göke R, Willemer S, Harthus H-P, Vermeer H, Arnold R, et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. European Journal of Clinical Investigation [Internet]. 1992 Apr 1 [cited 2019 Jul 11];22(4):283–91. Available from: http://doi.wiley.com/10.1111/j.1365-2362.1992.tb01464.x

30. Wewer Albrechtsen NJ, Kuhre RE, Toräng S, Holst JJ. The intestinal distribution pattern of appetite- and glucose regulatory peptides in mice, rats and pigs. BMC Research Notes [Internet]. 2016 Dec 2 [cited 2019 Mar 11];9(1):60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26830025

31. Kuhre RE, Holst JJ. Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine. Journal of Visualized Experiments [Internet]. 2019 Feb 26 [cited 2019 Aug 2];(144):e58533. Available from: https://www.jove.com/video/58533/mechanisms-underlying-gut-hormone-secretion-using-isolated-perfused

32. Kuhre RE, Christiansen CB, Saltiel MY, Wewer Albrechtsen NJ, Holst JJ. On the relationship between glucose absorption and glucose-stimulated secretion of GLP-1, neurotensin, and PYY from different intestinal segments in the rat. Physiological reports. 2017 Dec;5(23).

33. Gribble FM, Williams L, Simpson AK, Reimann F. A Novel Glucose-Sensing Mechanism Contributing to Glucagon-Like Peptide-1 Secretion From the GLUTag Cell Line. Diabetes [Internet]. 2003 May 1 [cited 2019 Jul 8];52(5):1147–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12716745

34. Parker HE, Adriaenssens A, Rogers G, Richards P, Koepsell H, Reimann F, et al. Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion. Diabetologia [Internet]. 2012 Sep 26 [cited 2019 Jul 8];55(9):2445–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22638549

35. Holst JJ. The Physiology of Glucagon-like Peptide 1. Physiological Reviews [Internet]. 2007 Oct [cited 2018 Feb 19];87(4):1409–39. Available from: http://www.physiology.org/doi/10.1152/physrev.00034.2006
36. de Heer J, Rasmussen C, Coy DH, Holst JJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia [Internet]. 2008 Dec 16 [cited 2019 Aug 2];51(12):2263–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18795252

37. Jia X, Brown JC, Kwok YN, Pederson RA, McIntosh CHS. Gastric inhibitory polypeptide and glucagon-like peptide-1(7–36) amide exert similar effects on somatostatin secretion but opposite effects on gastrin secretion from the rat stomach. Canadian Journal of Physiology and Pharmacology [Internet]. 1994 Oct [cited 2019 Aug 2];72(10):1215–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7882187

38. Gehart H, van Es JH, Hamer K, Beumer J, Kretzschmar K, Dekkers JF, et al. Identification of Enteroendocrine Regulators by Real-Time Single-Cell Differentiation Mapping. Cell [Internet]. 2019 Feb 21 [cited 2019 Sep 27];176(5):1158-1173.e16. Available from: https://www.sciencedirect.com/science/article/pii/S009286741831643X?via%3Dihub

39. Zhang C, Rigbolt K, Petersen SL, Biehl Rudkjær LC, Schwahn U, Fernandez-Cachon ML, et al. The preprohormone expression profile of enteroendocrine cells following Roux-en-Y gastric bypass in rats. Peptides [Internet]. 2019 Jun 15 [cited 2019 Jun 19];170100. Available from: https://www.sciencedirect.com/science/article/pii/S0196978119300786?dgcid=rss_sd_all

40. Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia [Internet]. 2018 Oct 22 [cited 2019 Aug 26];61(10):2098–107. Available from: http://link.springer.com/10.1007/s00125-018-4669-0

41. Osonoi T, Tamasawa A, Osonoi Y, Ofuchi K, Katoh M, Saito M. Canagliflozin Increases Postprandial Total Glucagon-Like Peptide 1 Levels in the Absence of α-Glucosidase Inhibitor Therapy in Patients with Type 2 Diabetes: A Single-Arm, Non-randomized, Open-Label Study. Diabetes Therapy [Internet]. 2019 Sep 10 [cited 2019 Sep 17];1:1–15. Available from: http://link.springer.com/10.1007/s13300-019-00689-w

42. Fahrenkrug J, Muckadell OBS de. Plasma secretin concentration in man: effect of intraduodenal glucose, fat, amino acids, ethanol, HCl, or ingestion of a meal. European Journal of Clinical Investigation [Internet]. 1977 Jun 1 [cited 2019 Aug 26];7(3):201–3. Available from: http://doi.wiley.com/10.1111/j.1365-2362.1977.tb01598.x

43. Boden G, Essa N, Owen OE, Reichle FA, Saraga W. Effects of intraduodenal administration of HCl and glucose on circulating immunoreactive secretin and insulin concentrations. The Journal of clinical investigation [Internet]. 1974 Apr 1 [cited 2019 Aug 26];53(4):1185–93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/4815082

44. Fahrenkrug J, Schaffalitzky De Muckadell OB, Holst JJ. Plasma Secretin Concentration in Anaesthetized Pigs after Intraduodenal Glucose, Fat, Aminoacids, or Meals with Various pH. Scandinavian Journal of Gastroenterology [Internet]. 1977 May 23 [cited 2019 Aug 26];12(3):273–9. Available from: http://www.tandfonline.com/doi/full/10.3109/00365527709180928

45. Holst JJ, Gribble F, Horowitz M, Rayner CK. Roles of the Gut in Glucose Homeostasis. Diabetes care [Internet]. 2016 Jun 1 [cited 2019 Sep 16];39(6):884–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27222546

46. Brodows RG, Chey WY. Physiological Doses of Secretin Do Not Stimulate Acute Insulin Release*. The Journal of Clinical Endocrinology & Metabolism [Internet]. 1980 Mar 1 [cited 2019 Aug 20];50(3):603–6. Available from: https://academic.oup.com/jcem/article-lookup/doi/10.1210/jcem-50-3-603
47. Ferrer RL, Medrano J, Calpena R, Diego M, Graells ML, Moltó M V., et al. Effect of Exogenous Cholecystokinin and Secretin on Pancreatic Secretion of Insulin and Glucagon in Rats: In Vivo Model Without Hepatic Filter. Digestive Diseases and Sciences [Internet]. 2001 [cited 2019 Aug 21];46(10):2127–33. Available from: http://link.springer.com/10.1023/A:1011994327575

48. Santeusanio F, Faloona GR, Unger RH. Suppressive effect of secretin upon pancreatic alpha cell function. The Journal of Clinical Investigation [Internet]. 1972 Jul 1 [cited 2019 Aug 26];51(7):1743–9. Available from: https://www.jci.org/articles/view/106975

49. Jensen SL, Fahrenkrug J, Holst JJ, Kühl C, Nielsen O V, Schaffalitzky de Muckadell OB. Secretory effects of secretin on isolated perfused porcine pancreas. The American journal of physiology [Internet]. 1978 Oct [cited 2019 Aug 26];235(4):E381-6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3300169

50. Florholmen J, Vonen B, Giaever AK, Burhol PG. The effect of secretin on the glucose-induced insulin release from isolated pancreatic islets in mice. Acta Physiologica Scandinavica [Internet]. 1987 Jun [cited 2019 Aug 26];130(2):237–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/696858

51. Hare KJ, Vilsboll T, Asmar M, Deacon CF, Knop FK, Holst JJ. The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action. Diabetes [Internet]. 2010 Jul 1 [cited 2019 Aug 26];59(7):1765–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20150286

52. Li Y, Schnabl K, Gabler S-M, Willershäuser M, Reber J, Karlas A, et al. Secretin-Activated Brown Fat Mediates Prandial Thermogenesis to Induce Satiation. Cell [Internet]. 2018 Nov 29 [cited 2019 Aug 2];175(6):1561-1574.e12. Available from: https://www.sciencedirect.com/science/article/pii/S0092867418313242
Figure 1

A. Distribution of Secretin in Human Tissue

B. Secretin (nM) over Time (min)

C. Area under the Curve (AUC) of Secretin

D. Distribution of Secretin in Human Tissue

E. Intensity of tissue weight adjusted

F. Hormone levels (pmol/L)

G. Immunohistochemistry staining

H. Average secretin positive cells
Figure 2

A

B

C

D

E

F

G

H

I

J
Figure 4

A. Distribution of the Secretin Receptor in Human Tissue

B. Secretin Receptor in Human Non-Diabetic Islets

C. Antibody ScTr-Pr Merge

D. 10 mM glucose

E. Average insulin (IU/mL)

F. 10 mM glucose

G. Average somatostatin (pm)

H. 10 mM glucose

I. Average glucagon (pm)